1,4-Diazepane-2,5-diones (2) are found to be a new class of potent LFA-1 inhibitors. The synthesis, structure, and biological evaluation of these 1,4-diazepine-2,5-diones and related derivatives are described.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2004.11.072 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correspondence regarding "Letter to the editor: TMS-evoked potentials provide novel neurophysiological features of Tourette syndrome".
Parkinsonism Relat Disord
January 2025
Center for Neurological Restoration, Neurological Institute, Cleveland Clinic, Ohio, United States. Electronic address:
Corrigendum to "Development and application of a novel aldehyde nanoparticle-based amplified luminescent proximity homogeneous assay forrapid quantitation of pancreatic stone protein" [Clin. Chim. Acta 535 (2022) 120-130].
Clin Chim Acta
January 2025
College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China. Electronic address:
ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update.
Ann Oncol
January 2025
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Background: The availability and affordability of safe, effective cancer therapies are core requirements for effective cancer control. Global disparities exist in access, however, yielding unequal cancer outcomes. The goal of this study was to provide updated data regarding the formulary availability, out-of-pocket costs, and accessibility of cancer medicines in countries across the full spectrum of economic development areas.
View Article and Find Full Text PDFClinicopathological features of porto-sinusoidal vascular disorder with a novel GIMAP5 mutation in a pair of twin siblings.
Dig Liver Dis
January 2025
Department of Pathology, Beijing Ditan Hospital, Captial Medical University, Beijing 100015, PR China. Electronic address:
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma.
Blood Rev
January 2025
Department of Hematology, First Hospital of Jilin University, Changchun, Jilin, China. Electronic address:
Multiple myeloma (MM) remains incurable and patients eventually face the relapse/refractory dilemma. B cell maturation antigen (BCMA)-targeted immunotherapeutic approaches have shown great effectiveness in patients with relapsed/refractory MM, mainly including chimeric antigen receptor T cells (CAR-T), bispecific T cell engagers (TCEs), and antibody-drug conjugates (ADCs). However, their impact on long-term survival remains to be determined.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!